overgeneralization ???? [Regulatives / Guidelines]

posted by luvblooms  – India, 2013-02-21 06:23 (4862 d 17:08 ago) – Posting: # 10089
Views: 10,245

Hi Helmut,

❝ Point taken. :no: Terribly sorry.


NO worries!!!

❝ My observations:

Guidance-bondage intrinsically tied to copy-and-paste-disease.

Lack of understanding even the most basic principles of GxP, PK, and good biostatistical practice (see the rather incomplete list in the post above).

Worst: A strong tendency to bend the rules (“make” analytical batches valid, dealing with outliers, etc.).


Totally agree to you on the Copy paste disease and lack of understanding of GxP and PK. Now coming to the rules/guidance (except “make” analytical batches valid, dealing with outliers) aren't they non binding recomendations :cool:.

❝ If the FDA requires the median you can’t use the mean without a justification.


Agreed!!!

❝ If you don’t know the cut-off it’s upon the PI’s discretion whether he excludes the subject right away or not. If a subject is already nauseous it may be unethical to continue blood sampling. Furthermore, the subject’s example may influence other volunteers. :vomit:

❝ However, if the PI decides to keep the subject in the study he may be excluded after calculating median tmax,ref of the rest of the group.


We have followed the same in our protocols and till now not received any query on the same (blame it to 30 minute review window)

❝ ❝ Will it be acceptable by EMEA or FDA? (Remember In principle any reason for exclusion is valid provided it is specified in the protocol and the decision to exclude is made before bioanalysis)


❝ That’s a gray area. No experience with the FDA.


FDA prefers the same thing, got some queries on the same and was suggested to do it the EMEA way.

❝ I use the mean instead (although teeth grinding). If we don’t know any value how can we state something in the protocol? See this post on what I use in my protocols. So far I never had a problem (which doesn’t mean a thing).


:-)

❝ BTW,Therefore, in the future I expect to see more useful information in PARs.


Agreed.

Now how about ER/MR/XR formulations as per the current guidelines??? 2 times median Tmax or τ (dosing interval)?

~A happy Soul~

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
127 visitors (0 registered, 127 guests [including 25 identified bots]).
Forum time: 00:32 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5